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Abstract
Background:  Exhaled breath condensate (EBC) is a non-invasive method to assess airway
inflammation and oxidative stress and may be useful in the assessment of childhood asthma.
Methods: Exhaled 8-isoprostane, a stable marker of oxidative stress, was measured in EBC, in
children (5–17 years) with asthma (13 steroid-naïve and 12 inhaled steroid-treated) and 11 healthy
control.
Results: Mean exhaled 8-isoprostane concentration was significantly elevated in steroid-naïve
asthmatic children compared to healthy children 9.3 (SEM 1.7) vs. 3.8 (0.6) pg/ml, p < 0.01. Children
on inhaled steroids also had significantly higher 8-isoprostane levels than those of normal subjects
6.7 (0.7) vs. 3.8 (0.6) pg/ml, p < 0.01. Steroid-naïve asthmatics had higher exhaled nitric oxide
(eNO) than those of controls 28.5 (4.7) vs. 12.6 (1.5) ppb, p < 0.01. eNO in steroid-treated
asthmatics was similar to control subjects 27.5(8.8) vs. 12.6(1.5) ppb. Exhaled 8-isoprostane did not
correlate with duration of asthma, dose of inhaled steroids or eNO.
Conclusion:  We conclude that 8-isoprostane is elevated in asthmatic children, indicating
increased oxidative stress, and that this does not appear to be normalized by inhaled steroid
therapy. This suggests that 8-isoprostane is a useful non-invasive measurement of oxidative stress
in children and that antioxidant therapy may be useful in the future.
Introduction
Anti-inflammatory drugs such as inhaled corticosteroids
now are the mainstay of treatment in childhood asthma
but measurement of airway inflammation using tradi-
tional invasive procedures is not feasible in children.
Bronchial biopsy is invasive and non-invasive tests such as
spirometry do not represent the true state of inflamma-
tion [1]. Less invasive tests such as sputum induction may
be difficult in children.
Exhaled breath condensate analysis is simple to perform,
is effort-independent, non-invasive and rapid [2,3]. Vari-
ous mediators of inflammation and oxidative stress, such
as hydrogen peroxide, cysteinyl-leukotrienes, 8-isopros-
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tanes have been measured in exhaled breath condensate
and have been found to be elevated in adults with asthma
compared to values in normal control subjects [4,5].
However, there are few studies of exhaled breath conden-
sate in children.
Increased oxidative stress is a feature of airway inflamma-
tion in asthma and inflammatory cells, such as eosi-
nophils, neutrophils, macrophages, and mast cells all
produce reactive oxygen radicals [6]. 8-isoprostane is a
stable product formed by oxidative metabolism of arachi-
donic acid and appears to be a reliable marker of oxidative
stress [7]. 8-isoprostane is increased in exhaled breath
condensate in adult asthmatic and its concentration is
related to asthma severity [4]. We therefore measured 8-
isoprostane in exhaled breath of children with asthma
who were either steroid-naïve or treated with inhaled ster-
oids. We compared exhaled 8-isoprostane with the levels
of nitric oxide (NO) in exhaled air as this has previously
been used as a non-invasive marker of airway inflamma-
tion in asthma.
Methods
Study population
Normal and asthmatic children 2–18 years of age who
were able to co-operate with the measurements were
enrolled into the study. The diagnosis of asthma was
based on a history of repetitive cough, breathlessness and
wheeze responsive to bronchodilators with or without
inhaled steroid [8]. Children with concomitant chronic
airway disease like cystic fibrosis or those suffering from
an exacerbation during the study period were excluded.
Stable steroid-treated asthmatic children were recruited
from the Pediatric Outpatient Clinics of Royal Brompton
Hospital. The asthmatic children not on inhaled steroids
(steroid-naïve) and normal controls were recruited from a
local church community or from relatives of staff.
Informed and written consent was obtained from parent/
s or guardian/s and the study was approved by the
Research Ethics Committee of Royal Brompton and Hare-
field NHS Trust.
Study design
Children on inhaled corticosteroids (n = 12) were divided
into two groups; those on ≤ 600 µg/day (low-dose group,
n = 6) and those on >600 µg/day (high-dose group, n = 6).
Atopic status was assessed by skin prick test to 4 common
allergens (grass pollen, house dust mite, cat hair and
Aspergillus fumigatus [Alk Abello, Denmark]). Exhaled NO
[9] and spirometry were measured; followed by collection
of exhaled breath condensate. In a separate group of 10
steroid-treated asthmatic children, the exhaled breath
condensate collections were performed twice 10 minutes
apart to assess the reproducibility of the test.
Exhaled NO measurement
Exhaled NO was measured by a single breath technique
using a chemiluminescence analyser (NiOx analyzer, Aer-
ocrine, Stockholm, Sweden) at an expired flow of 50 ml/
second. This equipment has a sensitivity of ± 1.5 ppb and
a precision of ± 2.5 ppb. A direct digital reading is
obtained and average of two readings was taken in each
child. As spirometric maneuvers are known to affect NO
readings, exhaled NO measurement was done prior to
lung function testing.
Spirometry
The airway function determination was performed by dry
spirometer (Vitalograph, Buckingham, UK). The highest
of three consecutive measurements was taken. FEV1 % pre-
dicted was calculated for each child.
Exhaled breath condensate analysis
Subjects breathed tidally for 10 minutes into the con-
denser (Ecoscreen, Jaeger, Hoechberg, Germany), wearing
a nose clip. Exhaled condensate was frozen at -20°C
elsius, after defrosting the sample was aliquoted into
small plastic tubes and stored at -80°C for later analysis.
This has been shown not to affect 8-isoprostane concen-
trations over six months of storage [10].
8-isoprostane assay
8-isoprostane was assayed by an enzyme-linked immuno-
sorbent assay (Cayman Chemical, Ann Arbor, MI). The
lowest detection limit of the assay was 4.5 pg/ml and the
intra and interassay correlation coefficient was ≤ 10%
[10,11].
Data analysis
All data are expressed as means ± SEM. Comparison of
demographic data was done by Chi-square test. Continu-
ous data of two subgroups were tested for significant dif-
ference by unpaired Student's t-test for normally
distributed data. Correlations were performed by Pear-
son's test for normally distributed data, and by Spear-
man's test for non-Gaussian data. Significance was
considered when p < 0.05. Reproducibility was assessed
by Bland-Altman plot of the paired values of exhaled 8-
isoprostane of the asthmatic children [10,11].
Results
We studied 11 normal control subjects, 13 steroid-naïve
and 12 steroid-treated asthmatic children. There was no
significant difference in age and sex of children between
these three groups (Table 1). There were 11 mild intermit-
tent and 2 moderate persistent asthmatics in the steroid-
naïve group. In the steroid-treated group, 6 children were
using ≤ 600 µg/day of inhaled corticosteroids, and 6 were
using >600 µg/day. All the children in steroid-treated asth-
matic group were well-controlled. 24 of the subjects wereRespiratory Research 2005, 6:79 http://respiratory-research.com/content/6/1/79
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skin prick test positive to at least one of the 4 common
tested aeroallergens (grass pollen, house dust mite, cat
hair and Aspergillus fumigatus). The mean eNO was signif-
icantly raised in steroid-naïve asthmatic children (28.5 ±
4.7 ppb) compared to normal subjects (12.6 ± 1.5 ppb, p
< 0.01), but was not significantly increased in the steroid-
treated group compared to the healthy controls (27.5 ±
8.8 ppb, p = 0.11). There was a wide scatter of eNO levels
in the steroid-treated group.
8-isoprostane was detected in 24/36 subjects. Mean
exhaled 8-isoprostane was higher in asthmatic children
who were not on inhaled steroid therapy compared to
that in the normal children (9.3 ± 1.7 vs 3.8 ± 0.6 pg/ml,
p < 0.01). The asthmatic children using inhaled steroids
had a trend towards lower 8-isoprostane levels than that
of steroid-naïve group (6.7 ± 0.7 vs 9.3 ± 1.7 pg/ml respec-
tively, p = 0.18); their results were significantly higher
than in control subjects (6.7 ± 0.7 vs 3.8 ± 0.6 pg/ml, p <
0.01) (Fig. 1).
There was no correlation between 8-isoprostane concen-
trations and exhaled NO (Fig. 2) or FEV1% predicted. 8-
isoprostane did not correlate with duration of asthma or
the prescribed dose of inhaled steroids. The levels of
exhaled 8-isoprostane in the low-dose and high-dose sub-
groups of steroid-treated asthmatic children were 6.5 ± 1.0
and 7.0 ± 1.1 pg/ml respectively (p > 0.05).
The second group of asthmatic children on whom repro-
ducibility of the measurements was analyzed comprised
of 10 inhaled steroid-treated asthmatics (4 females, mean
age 12.3 years, range 10 to 14.5 years). The doses of
inhaled steroids in these children ranged from 200 to
2000 µg/day. We found that the Bland-Altman plot of
repeat values of 8-isoprostane performed 10 minutes
apart in these 10 asthmatic children demonstrated good
reproducibility. The intra-class correlation coefficient
(ICC) of the two readings was 0.98 and the correlation
coefficient (r) was 0.98 (95% confidence interval of 0.92
to 1.00).
Discussion
We have shown that 8-isoprostane is detectable in exhaled
breath condensate of children, with significantly higher
concentrations in exhaled breath of asthmatic children
compared to healthy controls. Steroid-treated asthmatic
patients had a trend towards lower levels of 8-isoprostane
in exhaled breath, although the concentrations were still
significantly higher than in normal subjects. When the
exhaled breath condensate was assessed for reproducibil-
ity of 8-isoprostane it was found to be highly reproducible
(ICC = 0.98).
We studied 36 children, including steroid-naïve asthmat-
ics, asthmatic patients on inhaled steroids and normal
controls. The children were age and sex-matched and the
youngest child who was able to undertake the test was 5
years. Measurement of 8-isoprostane is a useful marker to
assess the oxidative stress of asthma in vivo, since it is a sta-
ble product of oxidative metabolism. Our study revealed
that asthmatic children had significantly higher levels of
exhaled 8-isoprostane than those in healthy volunteers. 8-
isoprostane is predominantly formed by oxidative metab-
olism of arachidonic acid via a non-enzymatic reaction,
but a small amount of 8-isoprostane may be formed by a
cyclooxygenase pathway [7]. Measurement of 8-isopros-
tane appears to be a reliable biomarker of oxidative stress.
The higher concentrations of exhaled 8-isoprostane in
exhaled breath condensates of children with asthma indi-
cates increased oxidative stress in asthmatic airways. The
levels are lower but still significantly greater than normal
in children treated with inhaled steroid therapy, indicat-
ing that anti-inflammatory treatment does not abolish
oxidative stress even their asthma control appears good.
However measurement of 8-isoprostane in a group of
asthmatic children before and after the initiation of ster-
oids is needed in future studies to determine the response
Table 1: Clinical characteristics of study population
Parameter Normal Controls Steroid-naïve asthmatic 
children
Steroid-treated asthmatic 
children
p value
Number 11 13 12 -
F e m a l e s 787N S
Mean age (years) 11.4 10.8 10.7 NS
Atopic children 5 12 7 NS
Mean FEV1 (% Predicted) 85 83 90 NS
Mean exhaled NO (ppb) 11.9 28.5* 27.5 <0.01
*p < 0.05 compared to levels in normal children.
NS = non-significant.Respiratory Research 2005, 6:79 http://respiratory-research.com/content/6/1/79
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to steroid therapy. In the present study, there was no
correlation between exhaled 8-isoprostane and the dose
of inhaled steroids in steroid-treated asthmatic children.
However, we were unable to compare 8-isoprostane con-
centrations with those in the bronchoalveolar lavage
fluid, as the latter is difficult to perform and not ethically
justifiable purely for research in children. In our study, no
correlation was seen between 8-isoprostane and exhaled
NO or FEV1% predicted. This temporal measurement
would enable us to determine the utility of exhaled 8-iso-
prostane in predicting an attack of asthma. In the steroid-
naïve group most patients were mild and we did not have
enough patients with severe disease to study whether
exhaled 8-isoprostane levels reflects disease severity as in
adults [4]. We found that exhaled breath condensate
measurement of 8-isoprostane was highly reproducible
when repeated measurements were made in 10 asthmatic
subjects.
We found that eNO was significantly higher in asthmatic
children compared to normal controls, but were reduced
in steroid-treated patients, in agreement with other stud-
ies [12]. Other authors have measured active oxygen radi-
cals and documented oxidative stress in asthma [13]. We
have previously reported increased concentrations of 8-
isoprostane in adult asthmatics, but the exhaled 8-iso-
prostane concentrations were higher compared to those in
our study. This could be due to the different age groups
studied and the fact that the adult patients had more
severe asthma. The raised levels of exhaled 8-isoprostane
despite inhaled steroid therapy is consistent with the sup-
position that 8-isoprostane is derived predominantly via
Exhaled 8-isoprostane in normal, steroid-naïve asthmatic and steroid-treated asthmatic children Figure 1
Exhaled 8-isoprostane in normal, steroid-naïve asthmatic and steroid-treated asthmatic children.Respiratory Research 2005, 6:79 http://respiratory-research.com/content/6/1/79
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the non-enzymatic peroxidation. This elevation in
exhaled 8-isoprostane in steroid-treated asthmatics is con-
sistent with the studies of other authors [14,15]. In our
study, it can be seen that eNO and 8-isoprostane appear
to respond differently to inhaled steroid therapy and no
correlation existed between eNO and exhaled 8-isopros-
tane. This indicates that a single mediator cannot serve as
a global marker of inflammation in asthma and it may be
necessary to measure more than one exhaled marker.
Our study shows that elevated 8-isoprostane is detectable
in the exhaled breath condensates of children with
asthma and may be used as a non-invasive measurement
of oxidative stress in childhood asthma. The persistence of
high levels of 8-isoprostane in spite of inhaled steroids
suggests that other treatments such as anti-oxidants might
be beneficial.
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